**Core Concept**
Hyperprolactinemia is a condition characterized by elevated levels of prolactin in the blood, which can be caused by various factors, including certain medications. Prolactin is a hormone produced by the pituitary gland, and its secretion is regulated by the dopamine-inhibitory pathway. Dopamine inhibits the release of prolactin, while its deficiency or blockade leads to hyperprolactinemia.

**Why the Correct Answer is Right**
Metoclopramide is a dopamine D2 receptor antagonist, which means it blocks the action of dopamine in the brain. By inhibiting dopamine receptors, metoclopramide disrupts the dopamine-inhibitory pathway, leading to an increase in prolactin secretion. This results in hyperprolactinemia, a common side effect of metoclopramide, particularly with long-term use. The mechanism of metoclopramide-induced hyperprolactinemia is a classic example of how a medication can affect hormone regulation through the inhibition of a neurotransmitter.

**Why Each Wrong Option is Incorrect**
**Option A:** Bromocriptine is a dopamine D2 receptor agonist, which means it stimulates dopamine receptors. By activating dopamine receptors, bromocriptine increases the inhibitory tone on prolactin secretion, leading to a decrease in prolactin levels, not an increase.

**Option B:** Levodopa is a precursor to dopamine and is used in the treatment of Parkinson's disease. While levodopa can increase dopamine levels in the brain, it does not directly affect the dopamine-inhibitory pathway on prolactin secretion.

**Option C:** Amantadine is an antiviral medication that also has some dopaminergic effects, but it is not a dopamine D2 receptor antagonist. Amantadine's effects on prolactin levels are not as well-characterized as those of metoclopramide.

**Clinical Pearl / High-Yield Fact**
When prescribing medications with potential prolactin-elevating effects, such as metoclopramide, it is essential to monitor patients for signs of hyperprolactinemia, including galactorrhea, amenorrhea, and erectile dysfunction. This is particularly important in patients with a history of prolactin-related disorders or those taking other medications that may interact with the dopamine-inhibitory pathway.

**✓ Correct Answer: D. Metoclopramide**